Your session is about to expire
← Back to Search
BH3120 for Solid Tumors
Study Summary
This trial is testing a new drug called BH3120 in patients with advanced or metastatic solid tumors. The purpose of the trial is to determine the safety, tolerability, appropriate dosage, how the
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are new participants currently being recruited for this ongoing medical study?
"Indeed, as stated on clinicaltrials.gov, this study is currently in the recruitment phase. The trial was initially posted for public access on December 28th, 2023 and has been recently updated on January 29th, 2024."
At how many different venues can this clinical trial be accessed?
"In addition to Severance Hospital in Seoul and Asan Medical Center in Hackensack, there are several other locations where patients can enroll for this clinical trial. These include the John Theurer Cancer Center at Hackensack University Medical Center in Cincinnati, as well as nine other sites."
Has the BH3120 received approval from the FDA?
"The safety of BH3120 is currently rated 1 on a scale from 1 to 3 by our team at Power. This rating reflects the limited data available regarding its safety and efficacy, as it is still in Phase 1 of clinical trials."
What is the primary goal of conducting this clinical trial?
"The primary outcome of this study, as reported by the trial sponsor Hanmi Pharmaceutical Company Limited, will be to determine the incidence and nature of dose-limiting toxicities (DLTs) throughout the entire study period until 90 days after the last treatment. Secondary outcomes include evaluating the objective response rate (ORR), defined as the proportion of participants with a confirmed complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additionally, disease control rate (DCR) will be measured as the proportion of participants with confirmed complete response, partial response, or stable disease according to RECIST v"
What is the current number of participants being enrolled in this clinical investigation?
"To fulfill the requirements of this trial, a total of 191 eligible participants must be enrolled. Patients from different locations including Severance Hospital in Seoul, New jersey, and Asan Medical Center in Hackensack, Ohio can participate in this study."
Share this study with friends
Copy Link
Messenger